Jennifer Minai-Azary
Finanzdirektor/CFO bei CONTEXT THERAPEUTICS INC.
Vermögen: 79 200 $ am 31.05.2024
Profil
Jennifer Minai-Azary is currently the Director at KAHR Medical Ltd., Treasurer at Millendo Therapeutics US, Inc., and Chief Financial Officer & Treasurer at Context Therapeutics, Inc. She previously worked as the Director-Technical Accounting at PAREXEL International Corp.
and Vice President-Finance at Millendo Therapeutics, Inc. Ms. Minai-Azary has an undergraduate and graduate degree from the University of Michigan.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
21.03.2024 | 40 000 ( 0,05% ) | 79 200 $ | 31.05.2024 |
Aktive Positionen von Jennifer Minai-Azary
Unternehmen | Position | Beginn |
---|---|---|
CONTEXT THERAPEUTICS INC. | Finanzdirektor/CFO | 01.11.2021 |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Direktor/Vorstandsmitglied | 11.07.2022 |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Treasurer | - |
Ehemalige bekannte Positionen von Jennifer Minai-Azary
Unternehmen | Position | Ende |
---|---|---|
PAREXEL INTERNATIONAL CORPORATION | Corporate Officer/Principal | - |
MILLENDO THERAPEUTICS | Finanzdirektor/CFO | - |
Ausbildung von Jennifer Minai-Azary
University of Michigan | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
CONTEXT THERAPEUTICS INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Millendo Therapeutics, Inc.
Millendo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics, Inc. is a biopharmaceutical company, which engages in seeking distinct and transformative treatments where there is a significant unmet medical need. The company was founded by Julia C. Owens in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |
PAREXEL International Corp.
PAREXEL International Corp. Miscellaneous Commercial ServicesCommercial Services PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA. | Commercial Services |
KAHR Medical Ltd.
KAHR Medical Ltd. Pharmaceuticals: MajorHealth Technology KAHR Medical Ltd. develops novel fusion protein pharmaceuticals for the treatment of cancer and autoimmune diseases. Its drug pipeline is built around the signal converter proteins a unique class of multi-functional therapeutic agents that convert signals sent from one cell to another. The firm?s therapeutic proteins integrate two functional units, enabling each one to elicit multiple cooperative functional endpoints. The company was founded by Mark L. Tykocinski in 2005 and is headquartered in Jerusalem, Israel. | Health Technology |
Millendo Therapeutics US, Inc.
Millendo Therapeutics US, Inc. Pharmaceuticals: MajorHealth Technology Millendo Therapeutics US, Inc. engages in the development of novel treatment for adrenal cancer. It focuses on developing a portfolio of disease-modifying treatments for endocrine disorders caused by hormone dysregulation. The company was founded by Raili E. Kerppola, Julia C. Owens, and Gary D. Hammer in January 2012 and is headquartered in Ann Arbor, MI. | Health Technology |